. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. OncoImmunology, 5(11) Immune checkpoint inhibitors have led to considerable therapy improvement in 54 cancer patients. Autoimmune side effects including skin reactions are frequently 55 observed. In melanoma those include rash and vitiligo and were shown to be 56 associated with a prolonged overall survival. Little is known about skin reactions in 57 NSCLC patients during immunotherapy. 58
Introduction 79
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung 80 cancers and can be divided into two major histological subtypes: adenocarcinoma 81 (AC) and squamous cell carcinoma (SCC). Standard first-line treatment of metastatic 82 disease consists of platinum-based chemotherapy. In selected molecular-defined 83 subgroups the first-line therapy is a targeted therapy using tyrosine kinase inhibitors 84 (TKI). 1 
85
The introduction of immunotherapy has significantly improved therapy outcome. Two 86 phase III trials with the anti-PD1 (anti-programmed death 1 receptor) antibody 87 nivolumab led to its approval in 2015 after it had been approved for metastatic 88 melanoma in 2014.
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89
PD1-checkpoint inhibitors block the interaction between PD1-receptors on T-cells 90
and their ligand PD-L1. Blocking PD1-receptors enhances T-cell response against 91 cancer cells. 6 In turn, activated T-cells can cause autoimmune-mediated side 92 effects, such as skin rash, colitis, hepatitis or pneumonitis. These are generally 93 manageable and reversible in most cases. Rash and pruritus are frequent immune-94 related dermatologic adverse reactions (skin irAEs) during immunotherapy, which 95 have been reported to occur in up to 25 % of melanoma patients. 4, 5, 7, 8 Toxicity data 96 for anti-PD1 approval in NSCLC reports skin irAEs in approximately 10% of patients 97
The aim of this study is to i) characterize skin irAEs in patients with advanced lung 105 cancer treated with nivolumab and ii) to specify the pattern of T-cell infiltration in 106 biopsies of these skin lesions. 107
Materials and Methods 110
Assessing tumor response to therapy with nivolumab and skin irAEs 111
After approval by the local ethics committee (EKSG Nr. 16/059) 
Immunohistochemistry analysis 124
Histology of punch biopsies from untreated skin rash was available from 4 patients, 125 of which 2 had SCC and 2 had AC. Biopsies of the SCC patients were taken from the 126 right forearm and right lower limb and of the AC patients from the right cheek and left 127 lower limb (one each, respectively). All punch biopsies had been performed by a 128 dermatologist. Histopathological analyses were conducted independently by a 129 pathologist and a dermatopathologist. From each representative paraffin-embedded6 skin block four microns-thick sections were obtained for HE and 131 immunohistochemistry (IHC) staining (CD3, CD4 and CD8). For each sample we 132 determined lymphocyte counts in the epidermis and dermis per 1mm 2 (= 4 random 133 high power fields). 134
Results 137
Tumor response and skin irAEs in NSCLC under nivolumab therapy 138
We identified 41 patients treated with at least one single dose of nivolumab. One 139 patient was excluded because consent was refused. Patient age ranged from 46 to 140 88 years (mean 65 years). 22 (55%) were male and 18 (45%) female (Table 1) . On 141 average, the 40 patients were treated with 7 cycles, ranging from 1 to 25 cycles. The 142 interval between treatment initiation and appearance of a skin irAE was 3 cycles. 143 23 (57%) of our patients had ACs, 14 (35%) SCCs and in 3 (8%) the tumor displayed 144 features of both subtypes (mixed subtype). 27 (67%) showed disease progression 145 under nivolumab therapy. We were unable to assess disease progression in one 146 individual because the patient had died due to ileus before a re-staging could be 147 performed. 148 7 (17%) developed a skin irAE under treatment. All skin reactions were classified 149 grade I or II (CTCAE 4.0). In this subpopulation 4 (57%) were scaly plaques ( Figure  150 1A/B) and 3 (43%) intense pruritus without visible skin lesions. Only 2 (29%) with 151 skin irAEs had PD, as opposed to all patients, where the majority had PD. 152
Furthermore, skin irAEs correlated with tumor responses in 5 of 12 responders (42%) 153 as compared to 2 of 27 non-responders (7%).
Immune infiltrate patterns of skin rash under nivolumab therapy correlates with 156
NSCLC subtype 157
Immunohistochemistry of the skin biopsies showed that the distribution of CD3+ T-158 cells in the inflammatory skin infiltrate was dependent on the cancer subtype ( Figure  159 1F/G). We observed an analogous cell distribution pattern among cytotoxic CD8+ T-160 cells. In patients with SCCs the lymphocyte infiltrates were more prominent above 161 the basal cell membrane whereas patients with ACs showed CD8+ T-cell infiltrates 162 more accentuated towards the dermis (Figure 2A-D) . Quantification of the T-cell 163 infiltrates further supported this observation: the ratios of CD8+ T-cells found in the 164 epidermis compared to all CD8+ T-cells of two patients with SCCs were 22% and 165 44%, respectively, while in two patients with ACs the ratios were 3% and 10%, 166 respectively (Figure 2A-D) . 
173
This was also reflected by our study. Several authors reported higher numbers of 174 skin irAEs in melanoma patients under nivolumab treatment. 4, 5, 7, 8 175 An association between appearance of skin irAEs and overall survival in melanoma 176 has been reported. [13] [14] [15] 17 Similarly, our data suggests an association between skin 177 irAEs and tumor response. The histological analysis of the rashes on the one hand 178 allowed us to rule out clinical differential diagnoses of eczema and psoriasis and on 179 the other hand revealed that the rashes were characterized by an inflammation rich Limitation of the study was the small sample size of 40 patients. One needs to keep 198 in mind that immunotherapy for treating NLCSCs has only recently been approved 199 and was provided through the early access program. We are confident that the 200 recent approval now enables broader access to immunotherapy, which will allow our 201 findings to be compared to future investigations from larger sample sizes. 202
In conclusion, our results suggest that the tissue tropism of lymphocytes in skin irAEs 203 may be more specific than previously known, opening new opportunities for 204 elucidating the underlying molecular mechanisms. T-cell count in the epidermis is greater among 2 SCC patients than among 2 AC 317 patients. 
